US EditionPublished • loading... • Updated
Weekly roundup: Success for Optimum clients in and out of the clinic – Optimum Strategic CommunicationsLink to: Bionical Emas and Pharma Resources Announce Exclusive Global Clinical Trial Supply PartnershipScroll to top
Summary by Optimum Strategic Communications
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
Weekly roundup: Success for Optimum clients in and out of the clinic – Optimum Strategic CommunicationsLink to: Bionical Emas and Pharma Resources Announce Exclusive Global Clinical Trial Supply PartnershipScroll to top
Poolbeg granted FDA Orphan Drug Designation for POLB 001 Poolbeg announced that the US Food and Drug Administration had granted Orphan Drug Designation to POLB 001 as an oral preventative therapy for T-cell engager bispecific antibody-induced Cytokine Release Syndrome. Nucleome Therapeutics appoints Bhavna Hunjan as Chief Business Officer Nucleome Therapeutics, a biotechnology company harnessing the power of non-coding […]
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
